EML4-ALK rearrangement of lung large cell neuroendocrine carcinoma: a case report.

ABSTRACT:

Background

Lung large cell neuroendocrine carcinoma (L-LCNEC) is a subtype of lung cancer with a low incidence and a high degree of malignancy. For early stage patients, surgical treatment is limited, and the risk of postoperative recurrence is high. For patients with unresectable or advanced disease, platinum-based chemotherapy is currently the mainstay of treatment, but its efficacy is unsatisfactory. L-LCNEC with the anaplastic lymphoma kinase (ALK) gene mutation is very rare and currently has no standard therapy. In this article, we report the case of a locally advanced L-LCNEC patient with ALK mutations who underwent first-line treatment with alectinib.

Case description

A previously healthy, 46-year-old, non-smoking woman was clinically diagnosed with unresectable local

SUBMITTER: Chen D 

PROVIDER: S-EPMC9929752 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature